Ursula S. Sandau
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ursula S. Sandau has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
- Julie Anne Saugstad
Department of Anesthesiology & Perioperative Medicine, Oregon Health & Science University, United States
4 shared publications - Juan Manuel Falcon-Perez
Exosomes Laboratory, Center for Cooperative Research in Biosciences (CIC bioGUNE) Basque Research and Technology Alliance (BRTA) Derio Spain
3 shared publications - Rienk Nieuwland
Laboratory of Experimental Clinical Chemistry, Laboratory Specialized Diagnostics & Research, Department of Laboratory Medicine Amsterdam UMC, University of Amsterdam Amsterdam The Netherlands
3 shared publications An Hendrix
Laboratory of Experimental Cancer Research, Department of Human Structure and Repair Ghent University Ghent Belgium
2 shared publications- Andrew Francis Hill
Institute for Health and Sport Victoria University Melbourne Australia
2 shared publications - Clotilde Théry
INSERM U932, Institut Curie Centre de Recherche, PSL Research University, F-75005, Paris, France
2 shared publications
Latest Publications
- Open Access
- 17 April 2026
- Published by Wiley in Journal of Extracellular Biology
- Vol. 5 (4) , e70136
Dysregulation of Extracellular Vesicle Concentration, MicroRNAs, and Surface Proteins in Patients With Niemann‐Pick Disease Type C
Niemann‐Pick disease type C (NPC) is a rare neurodegenerative disease primarily caused by mutations in the NPC1 gene, which is associated with cholesterol trafficking impairment, and disruption of endolysosomal processing and extracellular vesicles (EVs). Here, for patients with NPC1 mutations (NPC) and age‐matched controls (CTL) we describe the EV profile of dermal fibroblasts ( n = 5 NPC, n = 3 CTL) and, for the first time, cerebrospinal fluid (CSF, n = 5 NPC, n = 5 CTL). EVs were enriched using size‐exclusion chromatography and characterized by immunoblot, transmission electron microscopy, and microchip resistive pulse sensing. Single vesicle flow cytometry showed increased EV concentration in NPC CSF versus CTLs. In fibroblasts, EV concentration inversely correlated with NPC1 protein levels that was partially attenuated by hydroxypropyl‐β‐cyclodextrin, an experimental NPC therapeutic. Direct stochastic imaging and multiplexed EV immunoassays revealed that NPC EVs were enriched for endolysosomal proteins (CD63, Lamp1). Three miRNAs (miR‐365‐3p, ‐654‐3p, ‐598‐3p) were increased in NPC fibroblast EVs and two (miR‐320a, ‐199a/b‐3p) in NPC CSF EVs. Pathway analysis using those miRNAs identified relevant diseases and functions (cell death and survival, molecular transport, heredity neurological disease). These results demonstrate that NPC1 gene mutations alter EV biogenesis and disease‐associated changes in cargo that may serve as clinical biomarkers or therapeutic targets for NPC, a devastating disease without a cure.
- 17 April 2026
- Published by Wiley in Journal of Extracellular Biology
- Vol. 5 (4) , e70136
Open AccessDysregulation of Extracellular Vesicle Concentration, MicroRNAs, and Surface Proteins in Patients With Niemann‐Pick Disease Type C
Niemann‐Pick disease type C (NPC) is a rare neurodegenerative disease primarily caused by mutations in the NPC1 gene, which is associated with cholesterol trafficking impairment, and disruption of endolysosomal processing and extracellular vesicles (EVs). Here, for patients with NPC1 mutations (NPC) and age‐matched controls (CTL) we describe the EV profile of dermal fibroblasts ( n = 5 NPC, n = 3 CTL) and, for the first time, cerebrospinal fluid (CSF, n = 5 NPC, n = 5 CTL). EVs were enriched using size‐exclusion chromatography and characterized by immunoblot, transmission electron microscopy, and microchip resistive pulse sensing. Single vesicle flow cytometry showed increased EV concentration in NPC CSF versus CTLs. In fibroblasts, EV concentration inversely correlated with NPC1 protein levels that was partially attenuated by hydroxypropyl‐β‐cyclodextrin, an experimental NPC therapeutic. Direct stochastic imaging and multiplexed EV immunoassays revealed that NPC EVs were enriched for endolysosomal proteins (CD63, Lamp1). Three miRNAs (miR‐365‐3p, ‐654‐3p, ‐598‐3p) were increased in NPC fibroblast EVs and two (miR‐320a, ‐199a/b‐3p) in NPC CSF EVs. Pathway analysis using those miRNAs identified relevant diseases and functions (cell death and survival, molecular transport, heredity neurological disease). These results demonstrate that NPC1 gene mutations alter EV biogenesis and disease‐associated changes in cargo that may serve as clinical biomarkers or therapeutic targets for NPC, a devastating disease without a cure.
- Open Access
- 17 January 2025
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 14 (1) , e70036
Reproducibility of extracellular vesicle research
- 17 January 2025
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 14 (1) , e70036
Open AccessReproducibility of extracellular vesicle research
- Open Access
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S8)
Human cerebrospinal fluid extracellular vesicle miRNAs identify sex‐dependent changes in synaptic proteins in postmortem Alzheimer’s disease brain
Background: Alzheimer’s disease (AD) is the fifth leading cause of death for individuals aged 65 and older. Since FDA approved therapies have limited efficacy, there is a need to develop new treatments based on a better understand of pathological changes occurring in tissues from humans with AD. Central nervous system cells utilize extracellular vesicles (EVs) to package and secrete miRNAs where they mediate cell‐to‐cell communication. Importantly, cerebrospinal fluid (CSF) contains EVs derived from the brain whose contents – including miRNAs – reflect the originating cell’s molecular composition. Thus, we used CSF EV miRNAs to identify neurologically relevant genes and canonical pathways altered in the human AD brain.Method: Human CSF from AD (n = 28) and controls (n = 28) was fractionated by size exclusion chromatography to separate EVs. CSF EV miRNAs were assayed by qPCR and used for target prediction and Ingenuity Pathway Analysis. Human postmortem hippocampus from AD (n = 34) and control (n = 22) were used to measure SNAP‐25, MUNC18‐1, and Reelin by immunoblot. Human hippocampal sections were co‐labeled for SNAP‐25 and miR‐16‐5p in AD (n = 4) and control (n = 3). MiR‐16‐5p puncta were analyzed using Zen Intellesis AI Segmentation software.Result: Four miRNAs (miR‐16‐5p, ‐331‐3p, ‐409‐3p, ‐454‐3p) were significantly increased in AD CSF EVs compared to control EVs. Further, the increase in miR‐16‐5p and ‐331‐3p occurred only in AD females with APOEe3/e4 genotype. Conversely in males, miR‐16‐5p and ‐331‐3p showed no group differences. The predicted targets of miR‐16‐5p include mRNAs integral to synaptic transmission (SNAP‐25, MUNC18‐1, Reelin), which were significantly decreased in the hippocampus of AD females, compared to control females. While in males these protein targets were not changed in AD. Co‐labeling of human brain sections demonstrated that miR‐16‐5p and SNAP‐25 are both expressed in cortical grey matter and preliminary analysis shows a trend of increased miR‐16‐5p in AD.Conclusion: We demonstrate that the miRNA cargo of CSF EVs is impacted by AD, sex, and APOE4 status. Also, CSF EV miRNAs have the potential to identify therapeutic targets to treat or cure AD. These data also demonstrate pathological changes in AD are sex‐ and genotype‐dependent, which may need to be considered for drug development and/or treatment strategies.
- 1 December 2024
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (S8)
Open AccessHuman cerebrospinal fluid extracellular vesicle miRNAs identify sex‐dependent changes in synaptic proteins in postmortem Alzheimer’s disease brain
Background: Alzheimer’s disease (AD) is the fifth leading cause of death for individuals aged 65 and older. Since FDA approved therapies have limited efficacy, there is a need to develop new treatments based on a better understand of pathological changes occurring in tissues from humans with AD. Central nervous system cells utilize extracellular vesicles (EVs) to package and secrete miRNAs where they mediate cell‐to‐cell communication. Importantly, cerebrospinal fluid (CSF) contains EVs derived from the brain whose contents – including miRNAs – reflect the originating cell’s molecular composition. Thus, we used CSF EV miRNAs to identify neurologically relevant genes and canonical pathways altered in the human AD brain.Method: Human CSF from AD (n = 28) and controls (n = 28) was fractionated by size exclusion chromatography to separate EVs. CSF EV miRNAs were assayed by qPCR and used for target prediction and Ingenuity Pathway Analysis. Human postmortem hippocampus from AD (n = 34) and control (n = 22) were used to measure SNAP‐25, MUNC18‐1, and Reelin by immunoblot. Human hippocampal sections were co‐labeled for SNAP‐25 and miR‐16‐5p in AD (n = 4) and control (n = 3). MiR‐16‐5p puncta were analyzed using Zen Intellesis AI Segmentation software.Result: Four miRNAs (miR‐16‐5p, ‐331‐3p, ‐409‐3p, ‐454‐3p) were significantly increased in AD CSF EVs compared to control EVs. Further, the increase in miR‐16‐5p and ‐331‐3p occurred only in AD females with APOEe3/e4 genotype. Conversely in males, miR‐16‐5p and ‐331‐3p showed no group differences. The predicted targets of miR‐16‐5p include mRNAs integral to synaptic transmission (SNAP‐25, MUNC18‐1, Reelin), which were significantly decreased in the hippocampus of AD females, compared to control females. While in males these protein targets were not changed in AD. Co‐labeling of human brain sections demonstrated that miR‐16‐5p and SNAP‐25 are both expressed in cortical grey matter and preliminary analysis shows a trend of increased miR‐16‐5p in AD.Conclusion: We demonstrate that the miRNA cargo of CSF EVs is impacted by AD, sex, and APOE4 status. Also, CSF EV miRNAs have the potential to identify therapeutic targets to treat or cure AD. These data also demonstrate pathological changes in AD are sex‐ and genotype‐dependent, which may need to be considered for drug development and/or treatment strategies.
- Top Cited PapersOpen Access
- 7 February 2024
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 13 (2) , e12404
Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year‐on‐year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non‐vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its ‘Minimal Information for Studies of Extracellular Vesicles’, which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly.
- 7 February 2024
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 13 (2) , e12404
Top Cited PapersOpen AccessMinimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches
Extracellular vesicles (EVs), through their complex cargo, can reflect the state of their cell of origin and change the functions and phenotypes of other cells. These features indicate strong biomarker and therapeutic potential and have generated broad interest, as evidenced by the steady year‐on‐year increase in the numbers of scientific publications about EVs. Important advances have been made in EV metrology and in understanding and applying EV biology. However, hurdles remain to realising the potential of EVs in domains ranging from basic biology to clinical applications due to challenges in EV nomenclature, separation from non‐vesicular extracellular particles, characterisation and functional studies. To address the challenges and opportunities in this rapidly evolving field, the International Society for Extracellular Vesicles (ISEV) updates its ‘Minimal Information for Studies of Extracellular Vesicles’, which was first published in 2014 and then in 2018 as MISEV2014 and MISEV2018, respectively. The goal of the current document, MISEV2023, is to provide researchers with an updated snapshot of available approaches and their advantages and limitations for production, separation and characterisation of EVs from multiple sources, including cell culture, body fluids and solid tissues. In addition to presenting the latest state of the art in basic principles of EV research, this document also covers advanced techniques and approaches that are currently expanding the boundaries of the field. MISEV2023 also includes new sections on EV release and uptake and a brief discussion of in vivo approaches to study EVs. Compiling feedback from ISEV expert task forces and more than 1000 researchers, this document conveys the current state of EV research to facilitate robust scientific discoveries and move the field forward even more rapidly.
- Open Access
- 29 December 2023
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 13 (1) , e12397
Recommendations for reproducibility of cerebrospinal fluid extracellular vesicle studies
Cerebrospinal fluid (CSF) is a clear, transparent fluid derived from blood plasma that protects the brain and spinal cord against mechanical shock, provides buoyancy, clears metabolic waste and transports extracellular components to remote sites in the brain. Given its contact with the brain and the spinal cord, CSF is the most informative biofluid for studies of the central nervous system (CNS). In addition to other components, CSF contains extracellular vesicles (EVs) that carry bioactive cargoes (e.g., lipids, nucleic acids, proteins), and that can have biological functions within and beyond the CNS. Thus, CSF EVs likely serve as both mediators of and contributors to communication in the CNS. Accordingly, their potential as biomarkers for CNS diseases has stimulated much excitement for and attention to CSF EV research. However, studies on CSF EVs present unique challenges relative to EV studies in other biofluids, including the invasive nature of CSF collection, limited CSF volumes and the low numbers of EVs in CSF as compared to plasma. Here, the objectives of the International Society for Extracellular Vesicles CSF Task Force are to promote the reproducibility of CSF EV studies by providing current reporting and best practices, and recommendations and reporting guidelines, for CSF EV studies. To accomplish this, we created and distributed a world‐wide survey to ISEV members to assess methods considered ‘best practices’ for CSF EVs, then performed a detailed literature review for CSF EV publications that was used to curate methods and resources. Based on responses to the survey and curated information from publications, the CSF Task Force herein provides recommendations and reporting guidelines to promote the reproducibility of CSF EV studies in seven domains: (i) CSF Collection, Processing, and Storage; (ii) CSF EV Separation/Concentration; (iii) CSF EV Size and Number Measurements; (iv) CSF EV Protein Studies; (v) CSF EV RNA Studies; (vi) CSF EV Omics Studies and (vii) CSF EV Functional Studies.
- 29 December 2023
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 13 (1) , e12397
Open AccessRecommendations for reproducibility of cerebrospinal fluid extracellular vesicle studies
Cerebrospinal fluid (CSF) is a clear, transparent fluid derived from blood plasma that protects the brain and spinal cord against mechanical shock, provides buoyancy, clears metabolic waste and transports extracellular components to remote sites in the brain. Given its contact with the brain and the spinal cord, CSF is the most informative biofluid for studies of the central nervous system (CNS). In addition to other components, CSF contains extracellular vesicles (EVs) that carry bioactive cargoes (e.g., lipids, nucleic acids, proteins), and that can have biological functions within and beyond the CNS. Thus, CSF EVs likely serve as both mediators of and contributors to communication in the CNS. Accordingly, their potential as biomarkers for CNS diseases has stimulated much excitement for and attention to CSF EV research. However, studies on CSF EVs present unique challenges relative to EV studies in other biofluids, including the invasive nature of CSF collection, limited CSF volumes and the low numbers of EVs in CSF as compared to plasma. Here, the objectives of the International Society for Extracellular Vesicles CSF Task Force are to promote the reproducibility of CSF EV studies by providing current reporting and best practices, and recommendations and reporting guidelines, for CSF EV studies. To accomplish this, we created and distributed a world‐wide survey to ISEV members to assess methods considered ‘best practices’ for CSF EVs, then performed a detailed literature review for CSF EV publications that was used to curate methods and resources. Based on responses to the survey and curated information from publications, the CSF Task Force herein provides recommendations and reporting guidelines to promote the reproducibility of CSF EV studies in seven domains: (i) CSF Collection, Processing, and Storage; (ii) CSF EV Separation/Concentration; (iii) CSF EV Size and Number Measurements; (iv) CSF EV Protein Studies; (v) CSF EV RNA Studies; (vi) CSF EV Omics Studies and (vii) CSF EV Functional Studies.
- 31 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S5) , e057265
Utility of extracellular vesicles and their MicroRNA cargo as biomarkers for Alzheimer's disease
Background: Alzheimer’s disease (AD) is the most common cause of dementia. Developing effective therapies is dependent on the availability of biomarkers that accurately diagnosis AD and track disease progression. MiRNAs, which can be sorted into extracellular vesicles (EVs), reflect the disease state of many neurological disorders and have the potential to serve as biomarkers.Method: Cerebrospinal fluid (CSF) from AD, Parkinson’s disease (PD), and control (n=10/group) participants was analyzed by vesicle flow cytometry for size, concentration, and subtypes of EVs. In matching CSF and isolated CSF‐EVs we measured the expression of 34 miRNAs (previously validated candidate AD biomarkers) and assessed magnitude of fold change and classification potential for AD.Result: The EVs in CSF from AD and PD were significantly larger than control CSF and there were fewer microvesicles. CSF‐EVs had 25 detectable miRNAs out of 34 assayed; while 30 were detectable in total CSF. For the detectable miRNAs in CSF‐EVs, 52% had at least a 1.5 fold change in expression in AD, relative to control. In total CSF, 30% of the assayed miRNAs had a 1.5 fold change in AD versus control. Classification performance for AD from controls was improved for CSF‐EV miRNAs, compared to total CSF. Four of the CSF‐EV miRNAs also had an AUC > 0.7 for classifying AD from PD.Conclusion: EV biogenesis in neurodegenerative diseases is disrupted compared to neurologically normal controls, which leads to an altered EV profile in CSF. Further, the miRNA expression profile of CSF‐EVs improves the performance of candidate AD biomarkers.
- 31 December 2021
- Published by Wiley in Alzheimer's & Dementia
- Vol. 17 (S5) , e057265
Utility of extracellular vesicles and their MicroRNA cargo as biomarkers for Alzheimer's disease
Background: Alzheimer’s disease (AD) is the most common cause of dementia. Developing effective therapies is dependent on the availability of biomarkers that accurately diagnosis AD and track disease progression. MiRNAs, which can be sorted into extracellular vesicles (EVs), reflect the disease state of many neurological disorders and have the potential to serve as biomarkers.Method: Cerebrospinal fluid (CSF) from AD, Parkinson’s disease (PD), and control (n=10/group) participants was analyzed by vesicle flow cytometry for size, concentration, and subtypes of EVs. In matching CSF and isolated CSF‐EVs we measured the expression of 34 miRNAs (previously validated candidate AD biomarkers) and assessed magnitude of fold change and classification potential for AD.Result: The EVs in CSF from AD and PD were significantly larger than control CSF and there were fewer microvesicles. CSF‐EVs had 25 detectable miRNAs out of 34 assayed; while 30 were detectable in total CSF. For the detectable miRNAs in CSF‐EVs, 52% had at least a 1.5 fold change in expression in AD, relative to control. In total CSF, 30% of the assayed miRNAs had a 1.5 fold change in AD versus control. Classification performance for AD from controls was improved for CSF‐EV miRNAs, compared to total CSF. Four of the CSF‐EV miRNAs also had an AUC > 0.7 for classifying AD from PD.Conclusion: EV biogenesis in neurodegenerative diseases is disrupted compared to neurologically normal controls, which leads to an altered EV profile in CSF. Further, the miRNA expression profile of CSF‐EVs improves the performance of candidate AD biomarkers.
- Open Access
- 22 July 2021
- Published by Wiley in Journal of Neuroscience Research
- Vol. 99 (10) , 2364-2366
Toward a better understanding of inflammatory microvesicles in alcohol use disorder
- 22 July 2021
- Published by Wiley in Journal of Neuroscience Research
- Vol. 99 (10) , 2364-2366
Open AccessToward a better understanding of inflammatory microvesicles in alcohol use disorder
- Open Access
- 28 November 2020
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 10 (1) , e12028
Methamphetamine use alters human plasma extracellular vesicles and their microRNA cargo: An exploratory study
Methamphetamine (MA) is the largest drug threat across the globe, with health effects including neurotoxicity and cardiovascular disease. Recent studies have begun to link microRNAs (miRNAs) to the processes related to MA use and addiction. Our studies are the first to analyse plasma EVs and their miRNA cargo in humans actively using MA (MA‐ACT) and control participants (CTL). In this cohort we also assessed the effects of tobacco use on plasma EVs. We used vesicle flow cytometry to show that the MA‐ACT group had an increased abundance of EV tetraspanin markers (CD9, CD63, CD81), but not pro‐coagulant, platelet‐, and red blood cell‐derived EVs. We also found that of the 169 plasma EV miRNAs, eight were of interest in MA‐ACT based on multiple statistical criteria. In smokers, we identified 15 miRNAs of interest, two that overlapped with the eight MA‐ACT miRNAs. Three of the MA‐ACT miRNAs significantly correlated with clinical features of MA use and target prediction with these miRNAs identified pathways implicated in MA use, including cardiovascular disease and neuroinflammation. Together our findings indicate that MA use regulates EVs and their miRNA cargo, and support that further studies are warranted to investigate their mechanistic role in addiction, recovery, and recidivism.
- 28 November 2020
- Published by Wiley in Journal of Extracellular Vesicles
- Vol. 10 (1) , e12028
Open AccessMethamphetamine use alters human plasma extracellular vesicles and their microRNA cargo: An exploratory study
Methamphetamine (MA) is the largest drug threat across the globe, with health effects including neurotoxicity and cardiovascular disease. Recent studies have begun to link microRNAs (miRNAs) to the processes related to MA use and addiction. Our studies are the first to analyse plasma EVs and their miRNA cargo in humans actively using MA (MA‐ACT) and control participants (CTL). In this cohort we also assessed the effects of tobacco use on plasma EVs. We used vesicle flow cytometry to show that the MA‐ACT group had an increased abundance of EV tetraspanin markers (CD9, CD63, CD81), but not pro‐coagulant, platelet‐, and red blood cell‐derived EVs. We also found that of the 169 plasma EV miRNAs, eight were of interest in MA‐ACT based on multiple statistical criteria. In smokers, we identified 15 miRNAs of interest, two that overlapped with the eight MA‐ACT miRNAs. Three of the MA‐ACT miRNAs significantly correlated with clinical features of MA use and target prediction with these miRNAs identified pathways implicated in MA use, including cardiovascular disease and neuroinflammation. Together our findings indicate that MA use regulates EVs and their miRNA cargo, and support that further studies are warranted to investigate their mechanistic role in addiction, recovery, and recidivism.
- 1 October 2018
- Published by Elsevier in Brain Research
- Vol. 1697, 45-52
Correcting deregulated Fxyd1 expression rescues deficits in neuronal arborization and potassium homeostasis in MeCP2 deficient male mice
- 1 October 2018
- Published by Elsevier in Brain Research
- Vol. 1697, 45-52
Correcting deregulated Fxyd1 expression rescues deficits in neuronal arborization and potassium homeostasis in MeCP2 deficient male mice
- Open Access
- 30 November 2016
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 36 (48) , 12117-12128
Adenosine Kinase Deficiency in the Brain Results in Maladaptive Synaptic Plasticity
Adenosine kinase (ADK) deficiency in human patients (OMIM:614300) disrupts the methionine cycle and triggers hypermethioninemia, hepatic encephalopathy, cognitive impairment, and seizures. To identify whether this neurological phenotype is intrinsically based on ADK deficiency in the brain or if it is secondary to liver dysfunction, we generated a mouse model with a brain-wide deletion of ADK by introducing aNestin-Cretransgene into a line of conditional ADK deficient Adkfl/flmice. These AdkΔbrainmice developed a progressive stress-induced seizure phenotype associated with spontaneous convulsive seizures and profound deficits in hippocampus-dependent learning and memory. Pharmacological, biochemical, and electrophysiological studies suggest enhanced adenosine levels around synapses resulting in an enhanced adenosine A1receptor (A1R)-dependent protective tone despite lower expression levels of the receptor. Theta-burst-induced LTP was enhanced in the mutants and this was dependent on adenosine A2Areceptor (A2AR) and tropomyosin-related kinase B signaling, suggesting increased activation of these receptors in synaptic plasticity phenomena. Accordingly, reducing adenosine A2Areceptor activity in AdkΔbrainmice restored normal associative learning and contextual memory and attenuated seizure risk. We conclude that ADK deficiency in the brain triggers neuronal adaptation processes that lead to dysregulated synaptic plasticity, cognitive deficits, and increased seizure risk. Therefore, ADK mutations have an intrinsic effect on brain physiology and may present a genetic risk factor for the development of seizures and learning impairments. Furthermore, our data show that blocking A2AR activity therapeutically can attenuate neurological symptoms in ADK deficiency.SIGNIFICANCE STATEMENTA novel human genetic condition (OMIM #614300) that is based on mutations in the adenosine kinase (Adk) gene has been discovered recently. Affected patients develop hepatic encephalopathy, seizures, and severe cognitive impairment. To model and understand the neurological phenotype of the human mutation, we generated a new conditional knock-out mouse with a brain-specific deletion ofAdk(AdkΔbrain). Similar to ADK-deficient patients, AdkΔbrainmice develop seizures and cognitive deficits. We identified increased basal synaptic transmission and enhanced adenosine A2Areceptor (A2AR)-dependent synaptic plasticity as the underlying mechanisms that govern these phenotypes. Our data show that neurological phenotypes in ADK-deficient patients are intrinsic to ADK deficiency in the brain and that blocking A2AR activity therapeutically can attenuate neurological symptoms in ADK deficiency.
- 30 November 2016
- Published by Society for Neuroscience in Journal of Neuroscience
- Vol. 36 (48) , 12117-12128
Open AccessAdenosine Kinase Deficiency in the Brain Results in Maladaptive Synaptic Plasticity
Adenosine kinase (ADK) deficiency in human patients (OMIM:614300) disrupts the methionine cycle and triggers hypermethioninemia, hepatic encephalopathy, cognitive impairment, and seizures. To identify whether this neurological phenotype is intrinsically based on ADK deficiency in the brain or if it is secondary to liver dysfunction, we generated a mouse model with a brain-wide deletion of ADK by introducing aNestin-Cretransgene into a line of conditional ADK deficient Adkfl/flmice. These AdkΔbrainmice developed a progressive stress-induced seizure phenotype associated with spontaneous convulsive seizures and profound deficits in hippocampus-dependent learning and memory. Pharmacological, biochemical, and electrophysiological studies suggest enhanced adenosine levels around synapses resulting in an enhanced adenosine A1receptor (A1R)-dependent protective tone despite lower expression levels of the receptor. Theta-burst-induced LTP was enhanced in the mutants and this was dependent on adenosine A2Areceptor (A2AR) and tropomyosin-related kinase B signaling, suggesting increased activation of these receptors in synaptic plasticity phenomena. Accordingly, reducing adenosine A2Areceptor activity in AdkΔbrainmice restored normal associative learning and contextual memory and attenuated seizure risk. We conclude that ADK deficiency in the brain triggers neuronal adaptation processes that lead to dysregulated synaptic plasticity, cognitive deficits, and increased seizure risk. Therefore, ADK mutations have an intrinsic effect on brain physiology and may present a genetic risk factor for the development of seizures and learning impairments. Furthermore, our data show that blocking A2AR activity therapeutically can attenuate neurological symptoms in ADK deficiency.SIGNIFICANCE STATEMENTA novel human genetic condition (OMIM #614300) that is based on mutations in the adenosine kinase (Adk) gene has been discovered recently. Affected patients develop hepatic encephalopathy, seizures, and severe cognitive impairment. To model and understand the neurological phenotype of the human mutation, we generated a new conditional knock-out mouse with a brain-specific deletion ofAdk(AdkΔbrain). Similar to ADK-deficient patients, AdkΔbrainmice develop seizures and cognitive deficits. We identified increased basal synaptic transmission and enhanced adenosine A2Areceptor (A2AR)-dependent synaptic plasticity as the underlying mechanisms that govern these phenotypes. Our data show that neurological phenotypes in ADK-deficient patients are intrinsic to ADK deficiency in the brain and that blocking A2AR activity therapeutically can attenuate neurological symptoms in ADK deficiency.